Shin Nippon Biomedical Laboratories Beheer

Beheer criteriumcontroles 2/4

De CEO Shin Nippon Biomedical Laboratories is Ryoichi Nagata, benoemd in Jan1991, heeft een ambtstermijn van 33.83 jaar. bezit rechtstreeks 2.46% van de aandelen van het bedrijf, ter waarde € 9.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 9.4 jaar.

Belangrijke informatie

Ryoichi Nagata

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	33.8yrs
Eigendom CEO	2.5%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	9.4yrs

Recente managementupdates

Recent updates

CEO

Ryoichi Nagata (66 yo)

33.8yrs

Tenure

JP¥144,061,000

Compensatie

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ryoichi Nagata	President	33.8yrs	JP¥144.06m	2.46% € 10.0m
Fumihiko Makino	Senior Executive Officer	2.8yrs	geen gegevens	geen gegevens
Toshiyuki Iwata	Managing Executive Officer	no data	geen gegevens	geen gegevens
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	2.4yrs	geen gegevens	geen gegevens
Kyomi Nagatoshi	Senior Managing Executive Officer	no data	geen gegevens	geen gegevens
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	20.4yrs	geen gegevens	0.090% € 364.3k
Satoshi Matsumoto	Managing Executive Officer & GM of Fisheries Division	less than a year	geen gegevens	geen gegevens
Hideshi Tsusaki	Senior MD	1.8yrs	geen gegevens	geen gegevens
Terumasa Hirai	Managing Executive Officer & President and Representative Director of SNBL Ina Research Center	no data	geen gegevens	geen gegevens
Shu-Ichi Kanazashi	Managing Executive Officer	less than a year	geen gegevens	geen gegevens
Eishi Tsunozaki	Senior MD & Director	no data	geen gegevens	0.043% € 176.3k
Ichiro Nagata	Executive VP	no data	geen gegevens	40.32% € 163.5m

2.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YB3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ryoichi Nagata	President	41.6yrs	JP¥144.06m	2.46% € 10.0m
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	14.4yrs	geen gegevens	geen gegevens
Kyomi Nagatoshi	Senior Managing Executive Officer	no data	geen gegevens	geen gegevens
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	21.9yrs	geen gegevens	0.090% € 364.3k
Hideshi Tsusaki	Senior MD	10.4yrs	geen gegevens	geen gegevens
Eishi Tsunozaki	Senior MD & Director	10.4yrs	geen gegevens	0.043% € 176.3k
Ichiro Nagata	Executive VP	4.4yrs	geen gegevens	40.32% € 163.5m
Shinichi Fukumoto	Independent Outside Director	9.4yrs	geen gegevens	0.00096% € 3.9k
Takashi Yamashita	Independent Outside Director	9.4yrs	geen gegevens	0.00096% € 3.9k
Tsuyoshi Hanada	Independent Outside Director	4.4yrs	geen gegevens	0.0098% € 39.9k
Keiko Totani	Independent Outside Director	3.4yrs	geen gegevens	0.0019% € 7.8k
Chizuru Horishita	Independent Outside Director	less than a year	geen gegevens	geen gegevens

9.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YB3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.4 jaar).

Shin Nippon Biomedical Laboratories Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

No independent directors

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Recent updates

Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without Aura

Second quarter 2025 earnings released: EPS: JP¥29.04 (vs JP¥38.27 in 2Q 2024)

Investor sentiment improves as stock rises 19%

Upcoming dividend of JP¥20.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024

First quarter 2025 earnings released: EPS: JP¥2.94 (vs JP¥32.98 in 1Q 2024)

Investor sentiment deteriorates as stock falls 15%

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Full year 2024 earnings released: EPS: JP¥133 (vs JP¥146 in FY 2023)

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Third quarter 2024 earnings released: EPS: JP¥19.89 (vs JP¥1.63 loss in 3Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

New minor risk - Share price stability

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: JP¥38.26 (vs JP¥59.45 in 2Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024

Upcoming dividend of JP¥20.00 per share at 2.6% yield

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: JP¥32.99 (vs JP¥46.70 in 1Q 2023)

Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Now 20% undervalued after recent price drop

Full year 2023 earnings released: EPS: JP¥146 (vs JP¥171 in FY 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of JP¥30.00 per share at 1.4% yield

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: JP¥1.63 loss per share (vs JP¥41.89 profit in 3Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Investor sentiment deteriorated over the past week

No independent directors

Second quarter 2023 earnings released: EPS: JP¥59.45 (vs JP¥40.28 in 2Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥46.70 (vs JP¥43.86 in 1Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) made a tender offer to acquire Ina Research Inc. (TSE:2176) from its shareholder for ¥2.7 billion.

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: JP¥171 (vs JP¥87.94 in FY 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2022 Results on May 06, 2022

Upcoming dividend of JP¥40.00 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Special Dividend Guidance the Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥40.28 (vs JP¥11.91 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS JP¥43.86 (vs JP¥15.45 in 1Q 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Year Ending March 31, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥87.94 (vs JP¥61.25 in FY 2020)

Upcoming dividend of JP¥5.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2021 Results on May 10, 2021

New 90-day low: €4.86

Third quarter 2021 earnings released: EPS JP¥8.10 (vs JP¥17.49 in 3Q 2020)

New 90-day high: €5.70